Cart
0

Cancer Vaccines Market by Technology [Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines], Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End Use (Pediatrics and Adults) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_171453
Pages: 190
Jul 2017 | 3204 Views
 
Author's : Garima Chandra & Tanvi Sapatnekar
Tables: 57
Charts: 61
 

Cancer Vaccines Market Overview:

Global Cancer Vaccines Market is expected to reach at $12,814 million from $4,073 million and register a CAGR of 17.7%, during the forecast period, 2017 - 2023.

Vaccine is a biological preparation administered to produce acquired immunity in patients as well as healthy individuals. Cancer vaccines are a type of biological therapy that prevents and heals various types of cancer, such as, cervical cancer, prostate cancer, lung cancer, breast cancer, and others. These vaccines are designed specifically to recognize and reduce the growth of cancer cells by the immune system. Moreover, cancer vaccines are expected to reduce the prevalence and incidence rate of cancer.

The global cancer vaccines market is driven by increase in the prevalence of human papilloma virus (HPV) infections, administration of prophylactic cancer vaccines, high investments & government funding in the development of cancer vaccines, and launch of new cancer vaccines. However, high cost for developing cancer vaccines due to the need for frequently upgradation in manufacturing technology and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth. Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines are expected to offer lucrative opportunities in the near future.

 

Global Cancer Vaccines Market Segmentation

Global cancer vaccines market segmentation

Get more information on this report : Request Sample Pages

Segment Review

The global cancer vaccines market is segmented based on technology, type, indication, end use, and region. Based on technology, it is classified into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, and viral vector & DNA cancer vaccines. Based on type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. Based on indication, it is divided into cervical cancer, prostate cancer, and others. Based on end use, it is categorized into pediatric and adult vaccines. Regionally, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

India Cancer Vaccines Market

India cancer vaccines market

Get more information on this report : Request Sample Pages

The pediatric cancer vaccines segment possesses high market potential for growth in the market, owing to increase in traction of prophylactic vaccines among children. However, the adult cancer vaccines segment dominated the global market owing to increase in incidence of human papilloma virus infections in adults, for the forecast period. Furthermore, rise in cancer incidence in India cause approximately 6, 00,0007, 00,000 deaths, thus, growing the need for prophylactic and therapeutic cancer vaccines.

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to surpass that of the restraints. Moreover, emergence of new markets and increase in transition from prophylactic to therapeutic cancer vaccines is expected to provide new growth opportunities to the cancer vaccines market in the future.

Drivers, Restraints, and Opportunities

CANCER VACCINES MARKET  DRIVERS, RESTRAINTS, AND OPPORTUNITIES

Get more information on this report : Request Sample Pages

The key players profiled in the report are Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.

The other key players in the value chain include Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Galena Biopharma, Emergent Biosolutions, Prokarium, and ImmunoBiology Ltd.

Key Benefits of the Cancer Vaccines Market Report:

  • It provides an in-depth analysis, current trends, and future estimations to elucidate the imminent investment pockets
  • It presents a comprehensive analysis of factors that drive and restrict the market growth
  • It offers  quantitative analysis of the industry to enable the stakeholders to capitalize on the prevailing market opportunities
  • It highlights key segments of the industry to help in understanding the type of products and indications used globally
  • It profiles key market players and their strategies to comprehend the competitive outlook of the market

Cancer Vaccines Market Key Segments:

By Technology

  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Whole Cell Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines

By Type

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

By Indication

  • Cervical Cancer
  • Prostate Cancer
  • Others

By End Use

  • Pediatrics
  • Adults

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Argentina
    • Turkey
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rising prevalence of human papilloma virus (HPV) infections, causing cancers
3.6.1.2. Increasing administration of prophylactic cancer vaccines
3.6.1.3. Rising investments and government funding in the development of cancer vaccines
3.6.1.4. Launch and approval of new cancer vaccines in the market

3.6.2. Restraints

3.6.2.1. High cost for development of cancer vaccines due to the need of frequent upgradation in manufacturing technology
3.6.2.2. Longer timelines required for manufacturing a single vaccine

3.6.3. Opportunities

3.6.3.1. Increasing transition from prophylactic to therapeutic cancer vaccines
3.6.3.2. High growth prospects in emerging markets

Chapter: 4 CANCER VACCINES MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. DENDRITIC CELLS CANCER VACCINES

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. RECOMBINANT CANCER VACCINES

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. ANTIGEN/ADJUVANT CANCER VACCINES

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. WHOLE CELL CANCER VACCINES

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. VIRAL VECTOR AND DNA CANCER VACCINES

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

Chapter: 5 CANCER VACCINES MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. PREVENTIVE CANCER VACCINES

5.2.1. Market size and forecast

5.3. THERAPEUTIC CANCER VACCINES

5.3.1. Market size and forecast

Chapter: 6 CANCER VACCINES, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. CERVICAL CANCER

6.2.1. Market size and forecast

6.3. PROSTATE CANCER

6.3.1. Market size and forecast

6.4. OTHER INDICATIONS

6.4.1. Market size and forecast

Chapter: 7 CANCER VACCINES MARKET, BY END USE

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. PEDIATRICS

7.2.1. Market size and forecast

7.3. ADULTS

7.3.1. Market size and forecast

Chapter: 8 CANCER VACCINES MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Mexico market size and forecast
8.2.3.3. Canada market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. UK market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. Germany market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Argentina market size and forecast
8.5.3.3. Turkey market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

Chapter: 9 COMPANY PROFILES

9.1. ASTRAZENECA PLC. (MEDIMMUNE, LLC.)

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments

9.2. GLAXOSMITHKLINE PLC.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. MERCK & CO., INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments

9.4. SANOFI PASTEUR

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments

9.5. ADURO BIOTECH INC.

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments

9.6. SANPOWER GROUP CO., LTD.

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments

9.7. ASTELLAS PHARMA INC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments

9.8. CSL LIMITED

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments

9.9. PFIZER INC.

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments

9.10. SERUM INSTITUTE OF INDIA PVT. LTD.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 2. GLOBAL DENDRITIC CELLS CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL ANTIGEN/ADJUVANT CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL WHOLE CELL CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 8. GLOBAL PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL CANCER VACCINES MARKET FOR CERVICAL CANCER, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GLOBAL CANCER VACCINES MARKET FOR PROSTATE CANCER, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL CANCER VACCINES MARKET FOR OTHER INDICATIONS BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 15. GLOBAL CANCER VACCINES MARKET FOR PEDIATRICS, BY REGION, 2016-2023 ($MILLION)
TABLE 16. GLOBAL CANCER VACCINES MARKET FOR ADULTS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GLOBAL CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 19. NORTH AMERICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 20. NORTH AMERICA CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 23. EUROPE CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 25. EUROPE CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 26. EUROPE CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 27. EUROPE CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 28. ASIA-PACIFIC CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29. ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 33. LAMEA CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 34. LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 35. LAMEA CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 36. LAMEA CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
TABLE 37. LAMEA CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
TABLE 38. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 39. ASTRAZENECA: OPERATING SEGMENTS
TABLE 40. GSK: COMPANY SNAPSHOT
TABLE 41. GSK: OPERATING SEGMENTS
TABLE 42. MERCK: COMPANY SNAPSHOT
TABLE 43. MERCK: OPERATING SEGMENTS
TABLE 44. SANOFI: COMPANY SNAPSHOT
TABLE 45. SANOFI: OPERATING SEGMENTS
TABLE 46. ADURO: COMPANY SNAPSHOT
TABLE 47. ADURO: OPERATING SEGMENTS
TABLE 48. SANPOWER: COMPANY SNAPSHOT
TABLE 49. SANPOWER: OPERATING SEGMENTS
TABLE 50. ASTELLAS: COMPANY SNAPSHOT
TABLE 51. ASTELLAS: OPERATING SEGMENTS
TABLE 52. CSL: COMPANY SNAPSHOT
TABLE 53. CSL: OPERATING SEGMENTS
TABLE 54. PFIZER: COMPANY SNAPSHOT
TABLE 55. PFIZER: OPERATING SEGMENTS
TABLE 56. SERUM: COMPANY SNAPSHOT
TABLE 57. SERUM: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL CANCER VACCINES MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF CANCER VACCINES MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL CANCER VACCINES MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
FIGURE 7. BARGAINING POWER OF BUYERS
FIGURE 8. BARGAINING POWER OF SUPPLIERS
FIGURE 9. THREAT OF NEW ENTRANTS
FIGURE 10. THREAT OF SUBSTITUTION
FIGURE 11. COMPETITIVE RIVALRY
FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL CANCER VACCINES MARKET
FIGURE 13. U.S. CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 19. ITALY CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 20. SPAIN CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 25. AUSTRALIA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 28. ARGENTINA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 29. TURKEY CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
FIGURE 32. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
FIGURE 33. ASTRAZENECA: REVENUE BY SEGMENT, 2016 (%)
FIGURE 34. ASTRAZENECA: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 36. GSK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 39. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 42. SANOFI: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. ADURO: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. ADURO: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. ADURO: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. SANPOWER: NET SALES, 2014-2016 ($MILLION)
FIGURE 48. SANPOWER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. SANPOWER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. ASTELLAS: NET SALES, 2014-2016 ($MILLION)
FIGURE 51. ASTELLAS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. ASTELLAS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. CSL: NET SALES, 2014-2016 ($MILLION)
FIGURE 54. CSL: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. CSL: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. PFIZER: NET SALES, 2014-2016 ($MILLION)
FIGURE 57. PFIZER: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. SERUM: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. SERUM: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. SERUM: REVENUE BY GEOGRAPHY, 2016 (%)

 

The global cancer vaccines market is expected to register a significant growth, owing to the increase in vaccination against cervical and prostate cancers caused by human papilloma virus (HPV). The market has gained momentum due to the introduction of novel recombinant vaccines for the prevention of cervical cancers. In addition, increase in focus by key players on manufacturing cancer vaccines using dendritic cells supplement the market growth.

Cancer vaccines offer protection against cervical cancer, breast cancer, lung cancer, and prostate cancer, and others. However, cancer vaccines are used in the prevention of cervical cancers over the past few years. In addition, rise in incidence of cervical cancer in women, which affects approximately 500,000 women annually in 80% of the developing countries, has increased the demand for vaccines against human papilloma virus.

Vaccine development is a time-consuming process, which requires approximately 11–12 years for production before its commercial use. In addition, heavy financial investment in the manufacturing process of cancer vaccines restrains the growth of the market. However, emerging markets, such as Asia-Pacific and LAMEA, have taken initiatives to focus on the development of cancer vaccines, which offer lucrative opportunities for the market growth. The demand for cancer vaccines administered to pediatrics sector is expected to grow considerably in the near future, owing to the increase in demand for prophylactic vaccines in children, infants as well as adolescents and rise in incidence of childhood cancer. Furthermore, large number of therapeutic vaccines in the pipeline showcases the increase in focus of key market players on the development of therapeutic cancer vaccines such as, NeuVax (breast cancer), and ADXS-HPV (cervical cancer), and others.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Cancer Vaccines Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456 $3111
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840 $3456
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370 $4565
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450 $5160
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995 $6747
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo